Company Description
Pacira BioSciences, Inc. engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States.
The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature to targeted nerves.
It has a development and commercialization, and supply agreement with Aratana Therapeutics, Inc. for NOCITA, a bupivacaine liposome injectable suspension product.
The company was formerly known as Pacira Pharmaceuticals, Inc. and changed its name to Pacira BioSciences, Inc. in April 2019.
Pacira BioSciences, Inc. was incorporated in 2006 and is headquartered in Tampa, Florida.
| Country | United States |
| Founded | 2006 |
| IPO Date | Feb 3, 2011 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 712 |
| CEO | Frank Lee |
Contact Details
Address: 5401 West Kennedy Boulevard, Suite 890 Tampa, Florida 33609 United States | |
| Phone | 813 553 6680 |
| Website | pacira.com |
Stock Details
| Ticker Symbol | PCRX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001396814 |
| CUSIP Number | 695127100 |
| ISIN Number | US6951271005 |
| Employer ID | 51-0619477 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Frank D. Lee | Chief Executive Officer and Director |
| Daryl Gaugler | Chief Operating Officer |
| Kristen Williams J.D. | Chief Administrative Officer and Secretary |
| David M. Stack | Advisor |
| Charles A. Reinhart III, CPA, M.B.A. | Executive Officer |
| Dr. Jonathan Slonin M.D. | Chief Medical Officer |
| Shawn M. Cross | Chief Financial Officer |
| Lauren Bullaro Riker | Principal Accounting Officer and Senior Vice President of Finance |
| Susan Mesco | Head of Investor Relations |
| Anthony Molloy III, Esq. | Chief Legal and Compliance Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 13, 2024 | 144 | Filing |
| Dec 11, 2024 | DFAN14A | Filing |
| Nov 6, 2024 | 10-Q | Quarterly Report |
| Nov 6, 2024 | 8-K | Current Report |
| Oct 21, 2024 | 8-K | Current Report |
| Sep 27, 2024 | 8-K | Current Report |
| Sep 13, 2024 | 144 | Filing |
| Sep 9, 2024 | 8-K | Current Report |
| Aug 9, 2024 | 8-K | Current Report |
| Aug 2, 2024 | 144 | Filing |